Twitxy
Saved
@KFW_Lab's profile picture
View on X

Kelsey Fisher-Wellman, PhD

@KFW_Lab

Associate Professor - Wake Forest University School of Medicine. Research Focus - #Mitochondria and cancer
Winston-Salem, NC fisherwellmanlab.com Joined August 2018
960 Following 1.7K Followers 1.7K Posts

Latest posts 5

Pinned post

Kelsey Fisher-Wellman, PhD @KFW_Lab
Excited to announce that our work exploring the bioenergetics of blood cancer is now published at @eLife #Mitochondria, #CancerMetabolism
elifesciences.org/articles/63104
See original tweetorial for detailed summary and below for a few broader points.
elifesciences.org Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia Across a physiological span of ATP-free energy, leukemic mitochondria primarily consume, rather than produce, ATP.
Kelsey Fisher-Wellman, PhD @KFW_Lab May 24, 2021
Excited to share the lab’s first ever pre-print exploring the specific role of OXPHOS in AML! What we found might surprise you. Click👇 for paper access and please don't hesitate to provide some feedback. See🧵for details. @researchsquare
researchsquare.com/article/rs-642…
View quoted post on X
Kelsey Fisher-Wellman, PhD @KFW_Lab
📢Collaborative Project between our lab and the Jensen Lab at UNC-CH exploring the role of the #Mitochondria in MEK inhibitor cardiotoxicity -- Manuscript out today in @ScienceAdvances - science.org/doi/10.1126/sc…
www.science.org The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the... Cardiotoxicity induced by trametinib is associated with mitochondrial damage and resulting immune activation.
1 replies 1 reposts 13 likes 2.4K views View on X
Kelsey Fisher-Wellman, PhD @KFW_Lab
Collaboration between our group and the Tirosh lab exploring a novel mTOR activator (they devloped) in combination with ixazomib for treatment of Acute Myeloid Leukemia! - link.springer.com/article/10.118…
link.springer.com AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia Molecular Cancer - mTORC1 activity is oncogenic. However, in the presence of chemotherapy, suppression of mTORC1 is cytoprotective. mTOR suppression requires an intact tuberous sclerosis complex...
Kelsey Fisher-Wellman, PhD @KFW_Lab
New review from our group taking a critical look at OxPhos as a cancer target......and suggestions for where the field goes next. Published in @Biochem_Journal
portlandpress.com/biochemj/artic…
portlandpress.com Re-evaluating the rationale for targeting oxidative phosphorylation in acute myeloid leukemia Abstract. Targeting mitochondrial oxidative phosphorylation (OxPhos) has become a recurring strategy in the treatment of cancer, particularly in acute myeloid leukemia (AML). Early reports suggested...